Stay updated on Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page shows a new revision line: Revision: v3.6.6, replacing v3.6.5, indicating a small documentation update. This update concerns only metadata and does not alter the study details or visible content.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedRevision label updated from v3.6.4 to v3.6.5, reflecting a small maintenance update to the page and no alterations to the study details.SummaryDifference0.0%

- Check48 days agoChange Detected- Revision updated from v3.6.3 to v3.6.4, indicating a platform/software update to the site. The change does not alter any study data or visible content on the page.SummaryDifference0.0%

- Check69 days agoChange DetectedThe page revision label was updated to v3.6.3, replacing v3.6.2. This indicates a new version of the page's documentation rather than a content change.SummaryDifference0.0%

- Check76 days agoChange DetectedThe page revision label was updated from v3.6.0 to v3.6.2, signaling a newer build of the study detail page. This change affects only the page's metadata and does not alter the study content.SummaryDifference0.0%

- Check91 days agoChange DetectedNo longer looking for participants; new sections added for How to Read a Study Record, Common Questions, and How to Join a Study. Intervention/Treatment labeling was updated and the revision note changed to v3.6.0 from v3.5.5.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Carboplatin in Ovarian Cancer Clinical Trial page.